How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/socazolimab-cisplatin-carboplatin-paclitaxel-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab (Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent. Area:

phase 3 PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent PD-1, VEGF, microtubules, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab (Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab) — Lee's Pharmaceutical Limited. Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab TARGET	Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent	PD-1, VEGF, microtubules, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent class)

Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/socazolimab-cisplatin-carboplatin-paclitaxel-bevacizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab